Enorama Pharma AB (publ) (STO: ERMA)
Sweden
· Delayed Price · Currency is SEK 4.090
-0.140 (-3.31%)
Nov 20, 2024, 4:39 PM CET
Enorama Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 13.26 | 1.36 | 6.85 | 12.8 | 4.47 | 10.44 | Upgrade
|
| Revenue Growth (YoY) | 751.09% | -80.17% | -46.50% | 186.40% | -57.17% | -12.89% | Upgrade
|
| Cost of Revenue | 10.07 | 5.26 | 7.46 | 8.9 | 2.1 | 9.32 | Upgrade
|
| Gross Profit | 3.19 | -3.9 | -0.62 | 3.9 | 2.37 | 1.12 | Upgrade
|
| Selling, General & Admin | 31.72 | 34.39 | 37.83 | 29.99 | 24.53 | 23.66 | Upgrade
|
| Other Operating Expenses | -0.22 | -0.01 | -0.02 | -0.15 | 0.53 | 0.18 | Upgrade
|
| Operating Expenses | 34.89 | 37.92 | 41.35 | 31.23 | 25.38 | 24 | Upgrade
|
| Operating Income | -31.71 | -41.82 | -41.97 | -27.33 | -23.01 | -22.88 | Upgrade
|
| Interest Expense | -2.86 | -0.88 | -1.27 | -0.8 | -0.45 | -0.92 | Upgrade
|
| Interest & Investment Income | 0.08 | 0.08 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -1.99 | -1.99 | 0.96 | 0.19 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.92 | - | - | 0.2 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -35.55 | -44.61 | -42.28 | -27.74 | -23.46 | -23.8 | Upgrade
|
| Pretax Income | -35.55 | -44.61 | -42.03 | -27.74 | -23.46 | -23.8 | Upgrade
|
| Net Income | -35.55 | -44.61 | -42.03 | -27.74 | -23.46 | -23.8 | Upgrade
|
| Net Income to Common | -35.55 | -44.61 | -42.03 | -27.74 | -23.46 | -23.8 | Upgrade
|
| Shares Outstanding (Basic) | - | 28 | 8 | 6 | 6 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | - | 28 | 8 | 6 | 6 | 5 | Upgrade
|
| Shares Change (YoY) | - | 253.96% | 26.23% | 11.44% | 3.47% | 1.47% | Upgrade
|
| EPS (Basic) | - | -1.61 | -5.37 | -4.48 | -4.22 | -4.43 | Upgrade
|
| EPS (Diluted) | - | -1.61 | -5.37 | -4.48 | -4.22 | -4.43 | Upgrade
|
| Free Cash Flow | -46.56 | -41.35 | -32.96 | -30.22 | -24.51 | -27.91 | Upgrade
|
| Free Cash Flow Per Share | - | -1.49 | -4.21 | -4.88 | -4.41 | -5.19 | Upgrade
|
| Gross Margin | 24.03% | -287.26% | -9.00% | 30.45% | 52.92% | 10.73% | Upgrade
|
| Operating Margin | -239.11% | -3079.82% | -612.90% | -213.52% | -514.90% | -219.22% | Upgrade
|
| Profit Margin | -268.08% | -3285.20% | -613.85% | -216.75% | -524.86% | -228.07% | Upgrade
|
| Free Cash Flow Margin | -351.10% | -3044.85% | -481.35% | -236.14% | -548.47% | -267.47% | Upgrade
|
| EBITDA | -31.18 | -41.15 | -41.3 | -26.67 | -22.69 | -22.72 | Upgrade
|
| EBITDA Margin | -235.13% | - | - | -208.34% | - | -217.76% | Upgrade
|
| D&A For EBITDA | 0.53 | 0.68 | 0.67 | 0.66 | 0.32 | 0.15 | Upgrade
|
| EBIT | -31.71 | -41.82 | -41.97 | -27.33 | -23.01 | -22.88 | Upgrade
|
| EBIT Margin | -239.11% | - | - | -213.52% | - | -219.22% | Upgrade
|
| Revenue as Reported | 19.62 | 1.12 | 9.44 | 12.95 | 5.12 | 10.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.